2. Peptides
  3. Peptide and Derivatives
  4. Cell-adhesion Peptides

Cell-adhesion Peptides

Custom Peptide Synthesis

Cell-adhesion peptides mimic adhesive motifs derived from extracellular matrix proteins and regulate cellular adhesion, migration, proliferation, and differentiation by binding to cell surface receptors such as integrins. They are widely applied in biomaterial modifications and drug delivery systems.

Cell-adhesion Peptides (89):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P0023
    Cyclo(-RGDfK) 161552-03-0 99.83%
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
    Cyclo(-RGDfK)
  • HY-P0278
    RGD 99896-85-2 99.60%
    RGD is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
    RGD
  • HY-P1740
    RGD peptide (GRGDNP) 114681-65-1 99.83%
    RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation.
    RGD peptide (GRGDNP)
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) 862772-11-0 98.08%
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors.
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-12290
    Arg-Gly-Asp-Ser 91037-65-9 98.70%
    Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
    Arg-Gly-Asp-Ser
  • HY-P11753
    IKVAVC 1187540-64-2
    IKVAVC is a derivative peptide of IKVAV with an artificially added cysteine (Cys) at its C-terminus. IKVAVC retains all the biological activities of the original IKVAV, mainly acting as a neural adhesion/differentiation signaling peptide, and is equipped with an engineered linker arm that enables covalent conjugation to molecular materials. IKVAV inhibits the migration and activation of fibroblasts, downregulates the TGF-β1 signaling pathway and endoplasmic reticulum stress, and promotes nerve repair. IKVAV regulates the phenotype of macrophages, shifting them from the pro-inflammatory M1 type to the pro-reparative M2 type.
    IKVAVC
  • HY-P11780
    KAFDITYVRLKF 208116-26-1
    KAFDITYVRLKF is a selective, competitive integrin αvβ3 binder. KAFDITYVRLKF induces the production of MMP-9. KAFDITYVRLKF blocks monocyte migration, promotes melanoma cell migration, protects neurons, and improves motor and cognitive functions. KAFDITYVRLKF can be used in research related to melanoma and Parkinson's disease.
    KAFDITYVRLKF
  • HY-P11777
    AG73 170655-66-0
    AG73 is a polypeptide. AG73 is derived from the G domain of the Laminin α1 chain. AG73 binds heparin, Syndecan-1 and Syndecan-4. AG73 promotes the adhesion of various cells, induces the differentiation of salivary gland acinar cells, stimulates neurite outgrowth, secretion of matrix metalloproteinases and angiogenesis. AG73 retains its angiogenic activity when conjugated to chitosan membranes. AG73 can be used in the research of melanoma and ischemic injury.
    AG73
  • HY-P0290
    GRGDSP 91037-75-1 99.95%
    GRGDSP, a synthetic linear RGD peptide, is an integrin inhibitor.
    GRGDSP
  • HY-P0122
    iRGD peptide 1392278-76-0 98.49%
    iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
    iRGD peptide
  • HY-P0131A
    Laminin peptide CDPGYIGSR TFA 2828432-44-4 99.75%
    Laminin peptide CDPGYIGSR (Laminin (925-933)) TFA is a 67 kDa laminin receptor ligand and selective cell adhesion inducer. Laminin peptide CDPGYIGSR TFA not only promotes cell adhesion and mediates directed neurite outgrowth via matrix coating or covalent immobilization, but also inhibits neural crest cell migration under specific conditions. Laminin peptide CDPGYIGSR TFA inhibits lung colonization of melanoma cells, and suppresses the growth of Sarcoma 180 solid tumors and Lewis lung carcinoma (3LL) in mice. Laminin peptide CDPGYIGSR TFA also exerts significant anti-angiogenic effects by inhibiting embryonic angiogenesis in the chick chorioallantoic membrane and vascular endothelial cell migration induced by tumor-conditioned medium. Laminin peptide CDPGYIGSR TFA can be widely used in studies related to melanoma, Sarcoma 180, Lewis lung carcinoma (3LL), and other relevant areas.
    Laminin peptide CDPGYIGSR TFA
  • HY-P0023A
    Cyclo(-RGDfK) TFA 500577-51-5 99.61%
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
    Cyclo(-RGDfK) TFA
  • HY-P0322
    GRGDSPK 111119-28-9 98.55%
    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption.
    GRGDSPK
  • HY-P1740A
    RGD peptide (GRGDNP) TFA 99.94%
    RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation.
    RGD peptide (GRGDNP) TFA
  • HY-126437B
    Poly-L-lysine hydrobromide (MW 70000-150000) 25988-63-0
    Poly-L-lysine (hydrobromide) (MW 70000-150000), a positively charged amino acid polymer, is a nonspecific attachment factor for cells. Poly-L-lysine (hydrobromide) (MW 70000-150000) has good biocompatibility. Poly-L-lysine (hydrobromide) (MW 70000-150000) is used to increase cell adhesion to solid substrates by enhancing electrostatic interaction between negatively charged ions of the cell membrane and the culture surface.
    Poly-L-lysine hydrobromide (MW 70000-150000)
  • HY-P0295
    Gly-Arg-Gly-Asp-Ser 96426-21-0 99.35%
    Gly-Arg-Gly-Asp-Ser (GRGDS) is a pentapeptide that forms the cell-binding domain of a glycoprotein, osteopontin. Gly-Arg-Gly-Asp-Ser binds to integrin receptors αvβ3 and αvβ5 with estimated IC50 of ～5 and ～6.5 μM
    Gly-Arg-Gly-Asp-Ser
  • HY-P4322
    H-Ile-Lys-Val-Ala-Val-OH 131167-89-0 99.35%
    H-Ile-Lys-Val-Ala-Val-OH is one of the most potent active sites of laminin-1. H-Ile-Lys-Val-Ala-Val-OH promotes cell adhesion, neurite outgrowth, and tumor growth. H-Ile-Lys-Val-Ala-Val-OH stimulates BMMSC population growth and proliferation by activating MAPK/ERK1/2 and PI3K/Akt signalling pathways.
    H-Ile-Lys-Val-Ala-Val-OH
  • HY-P1408
    Obtustatin 404882-00-4 99.94%
    Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma.
    Obtustatin
  • HY-P3522
    REDV 107978-83-6 99.33%
    REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion. REDV is used to study the effects of gene vectors containing REDV on cells.
    REDV
  • HY-P0132
    YIGSR 110590-64-2 99.38%
    YIGSR (Laminin Fragment 929-933) is a polypeptide that inhibits tumor growth and metastasis of leukemia cells. YIGSR specifically binds to the 67kDa laminin receptor and regulates the expression of eNOS in endothelial cells. YIGSR can be used in leukemia-related research.
    YIGSR